Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials - Takeaways - MDSpire

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

  • By

  • Jerry Bagel

  • Ranga Gogineni

  • Asif Shaikh

  • Mark G. Lebwohl

  • March 16, 2026

  • 0 min

Share

  • 1

    Tildrakizumab demonstrated maintained efficacy in patients with moderate-to-severe plaque psoriasis and diabetes mellitus in reSURFACE trials.

  • 2

    Patients receiving tildrakizumab achieved significantly higher PASI 75 and PGA 0/1 responses at week 12 compared to placebo.

  • 3

    Treatment-emergent adverse events were more frequent in patients with diabetes, particularly those with comorbid obesity.

  • 4

    The study highlights the need to consider diabetes mellitus when assessing psoriasis treatment efficacy and safety.

  • 5

    Results from this analysis are consistent with overall findings from the reSURFACE 1 and reSURFACE 2 trials.

Original Source(s)

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

  • by Jerry Bagel, Ranga Gogineni, Asif Shaikh, Mark G. Lebwohl

  • March 16, 2026

Related Content

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse